Document Detail

Improvement of sympathetic skin responses under enzyme replacement therapy in Fabry disease.
MedLine Citation:
PMID:  16972173     Owner:  NLM     Status:  MEDLINE    
AIM: To report the effect of enzyme replacement therapy (ERT) in sympathetic skin responses (SSR) of patients with Fabry disease. PATIENTS AND METHODS: Seven male patients were included in an open-label protocol using agalsidase-alfa, continued at regular intervals. Five patients completed 24 months of ERT and two of them completed 18 months. Two main measurements were performed at baseline, as well as 1 and 2 years after ERT: (1) a standard neurological examination (NE), with a detailed evaluation of the sensory perception of light touch, pinprick, cold, hot, and vibratory stimuli; (2) the SSR amplitudes. RESULTS: Although there were no significant differences between NE in this time period, all patients reported general improvement in their subjective reports of acroparaesthesia and sweating. Before starting ERT, the SSR amplitudes were either too small (3/7 patients) or absent (4/7 patients): the average (range) amplitude of 122 microV (0 through 492) was statistically smaller than that found in a control group, i.e. 1453.6 microV (619.7-2754) (p<0.0001, t-test). Mean +/- SD SSR amplitude increased to 1088+/- 690 microV in the second year of ERT, reaching the range found in a normal control group (p=0.004). CONCLUSION: ERT improved SSR continuously in Fabry patients in 2 years of observation. Although the mechanism of the SSR improvement is unknown, this response to ERT can be clinically significant if it reflects a normalization in sweating.
L B Jardim; I Gomes; C B O Netto; D B Nora; U S Matte; F Pereira; M G Burin; L Kalakun; R Giugliani; J Becker
Related Documents :
10570383 - Facial hirsutism treated with the normal-mode ruby laser: results of a 12-month follow-...
16418703 - Assessment of chronic exposure to mdma in a group of consumers by segmental hair analysis.
25264643 - Effect of marijuana use on outcomes in traumatic brain injury.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2006-07-27
Journal Detail:
Title:  Journal of inherited metabolic disease     Volume:  29     ISSN:  0141-8955     ISO Abbreviation:  J. Inherit. Metab. Dis.     Publication Date:  2006 Oct 
Date Detail:
Created Date:  2006-09-14     Completed Date:  2007-01-17     Revised Date:  2007-08-27    
Medline Journal Info:
Nlm Unique ID:  7910918     Medline TA:  J Inherit Metab Dis     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  653-9     Citation Subset:  IM    
Medical Genetics Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Data Bank Information
Bank Name/Acc. No.:
OMIM/301500; RefSeq/NM_000169
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Age Factors
Case-Control Studies
Child, Preschool
DNA Mutational Analysis
Enzymes / therapeutic use*
Fabry Disease / drug therapy*
Isoenzymes / pharmacology
Molecular Sequence Data
Neurologic Examination
Skin / pathology*
Time Factors
alpha-Galactosidase / pharmacology*
Reg. No./Substance:
0/Enzymes; 0/Isoenzymes; EC 3.2.1.-/agalsidase alfa; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Critical assessment of chitotriosidase analysis in the rational laboratory diagnosis of children wit...
Next Document:  Needs assessment and review of services for people with inherited metabolic disease in the United Ki...